Jan-Marc Lieskovsky

Germany's ambitious plan for digital transformation in healthcare is a great step forward! The outlined benefits are clear; reduced mortality rates, less bureaucracy, fewer medication errors, and earlier detection of complications. This all translates to better patient outcomes and a more efficient healthcare system. A lot to learn and adopt! #digitalhealth #healthcareinnovation

7

Big news: Xaira emerges out of stealth with $1 billion in funding to revolutionize drug discovery! Just two days after sharing my thoughts on AI's potential in healthcare, the Xaira Therapeutics launch proves we are at the moment where AI probably disrupts healthcare. With $1 billion in funding, Xaira is set to transform how we discover new drugs, making the process faster, more accurate, and potentially more cost-effective. Here's why this matters: ▶ AI can significantly shorten the drug development cycle. ▶ This means vital treatments could reach patients quicker. ▶ It could also lead to lower healthcare costs overall. For those of us passionate about the intersection of AI and healthcare, Xaira's emergence is a validation of the disruptive potential we've believed in. It is a complete overhaul in developing and delivering treatments. Big investor names are already committed with F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners how participated in the round. Dive deeper into this development and what it means for the future of healthcare on Fierce Healthcare’s article: “New AI drug discovery powerhouse Xaira rises with $1B in funding” This is a pivotal moment for healthcare innovation. AI will shape the future of drug discovery and patient care Source and picture: Fierce Healthcare’s: “New AI drug discovery powerhouse Xaira rises with $1B in funding” #Biotech #AIDrugDiscovery #Healthcare #Xaira

18

4 Kommentare

Healthcare startups and midsize companies looking to expand, as well as savvy investors must attend HLTH and HLTH Europe! Unlike traditional conferences, it's essential to engage in innovative opportunities, network with industry leaders, and participate in incredible programs like CONNECT to gain the full benefits. The entire conference is focused on networking (and enjoying great food), which is how you'll discover incredible opportunities. These events offer unparalleled benefits, including international prospects you won’t want to miss! Get ready to elevate your business and tap into global potential. Don’t miss out! 🌐 #HLTH #HLTHERP #HealthcareInnovation #StartupGrowth #InvestorOpportunity #GlobalExpansion

9

🚀 Digital Twins from Synthetic Data for Clinical Trials Attract OpenAI 🚀 The era of Digital Twins has finally arrived. Introduced in my 2018 book 'Your Guide to Delight,' the number of relevant publications starts to increase, first true applications become more mature, and novel creative applications emerge. See, for instance, my post on Saturday (May 10) on a sophisticated digital twin model that simulates real-life alcohol consumption and combines #biomarkers with a #digitalhealth app. On the eve of the 1st International Symposium on Digital Twins in Healthcare, here is some novel exciting news. Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, is expanding its board with a significant profile and achieving significant regulatory and business milestones. The company won approval from the European Medicines Agency (EMA) for using its AI-driven approach for conducting smaller and quicker clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck. Mira Murati, chief technology officer at OpenAI (from ChatGPT fame), is joining the startup's board. "The team at Unlearn is working on applications of AI that have incredible potential to revolutionize healthcare, diagnostics, and treatment." While #generativeAI is so far known for creating content like text, images, video, and even computer code, Unlearn uses it to build #digitaltwins to speed up clinical drug trials through its neural networks. They create so-called synthetic (patient) data. If successful, Unlearn's software could lower costs for drug developers by cutting the number of enrollments needed for clinical trials by replacing patients who receive a placebo. 🗣️ I will discuss these groundbreaking developments in my closing keynote at the 1st International Symposium on Digital Twins in Healthcare in Cyprus this week. Learn More Here: https://lnkd.in/eamYU4Ec 🎥 Dive deeper into how AI is revolutionizing healthcare by visiting my YouTube channel Koen Kas YouTube and explore more about our latest innovations and insights : https://lnkd.in/d47khtbg 🌐 For more details on my keynotes like "AI in Healthcare: Demystified and Destigmatised" and "How AI Will Propel Us from Healthy & Happy to Being Epic," visit my website https://lnkd.in/d2Quv5w3 📚 Also, don't miss out on pre-ordering my latest book "EPIC: Unleash your full potential through health, art, and technology": Dutch Edition Pre-Order: https://lnkd.in/d_Kbwph9 English Edition Pre-Order: https://lnkd.in/dxZ243ja Kudos to the Conference Chairs Adrian M. Ionescu and Andreani Odysseos and a special shoutout to Charles Fisher and his team for their groundbreaking work. #syntheticdata #digitaltwin #drugdiscovery #genAI #drugdevelopment #digitalhealth #pharma

110

6 Kommentare

Ever wonder what the Internet of Medical Things looks like in the MedTech industry? We discussed this in our Future trends in MedTech Innovation webinar last week but there’s nothing like a good pic to summarise what opportunities it brings to improving patient outcomes and QoA. Thanks Scilife

5

1 Kommentar

Rather than a selfie (which no ones wants) here a photo of some pretzels from health.tech (formerly bits n pretzels) Looking forward to presenting with Roche later today and meeting up with partners and colleagues #health.tech #ht24 #roche #rochediagnostics #pointofcare #digitalhealth

24

2 Kommentare

What I Don't Like About HealthTech Startups Over the last year or so, I have found startups very fascinating. Startups are the labs where research experiments come to life. However, one of the things that I don't like is when a startup claims that their solution helps to solve clinician burnout. What irritates me more is when the company has zero physicians on their founding or advisory board. Clinician burnout is not a problem with a single cause and an effective solution. Burnout has many causes, such as: 1- The emotional burden of medicine: No one talks about this. We, as physicians, are expected to see patients day in and day out without becoming emotionally involved. No one in medicine even debriefs after emotionally stressful events. A patient dies in the ICU or on the ward, we go and announce it, call the family who bursts into tears, and then we go home and continue our lives. 2- Hierarchy: No matter where you are in healthcare, you have a boss, someone to report to, and someone who holds you accountable. If you are in academia, you are in the pyramid of scientific growth and are required to publish a certain number of papers every month. If you are in private practice, you are asked to see a certain number of patients each day. 3- The working hours and the weekends: Many physicians have no control over their working hours. As we advance in training, we become more responsible and work more. Many physicians work 14 days straight when they are covering the weekends, something less heard of in other industries. 4- Administrative work at home: It is very amusing to me to talk to my friends who are not in healthcare and learn about what they do after they finish their work at 5 PM and have a quarter of the day to spend at home. In medicine, you never know when you are going to be home – maybe at 5, maybe at 6, or maybe at 7. Then, you still have administrative work to do at home, including notes, preparing for the next day's clinic, or completing patient forms. I can go on and on, but for the sake of this post, I will stop here. The bottom line is that no startup can solve physician burnout. They could help, for sure, but they can't solve it. #medtech #healthtech #startups #startup #digitalhealth #physicianburnout #burnout #healthcare

3

That’s <20% operational efficiency! Technique+duration+frequency- effective hand hygiene Traditional analog disconnected workplace washbasins are not fit for purpose for smart workplaces, when post covid workplace absenteeism is highest in a decade in U.K and has risen by up to 42% in USA. Washing hands 6-10 times decrease infection risk by up to 36% Handsteco AI digital twin tech enabled Health on Tap (HoT) zone provides Wash basin as Service (WbaS) for 100% operational efficiency. HoT App doesn’t monitor but rewards employees for compliance sustainably Handsteco HoT game transforms every workplace hand washing episode into a unit of digital disinfection of hands every day- Washing hands is good for health, Handsteco HoT game makes it better.

1

An important new paper from FDA, the agency lays out its thinking on transparency in AI. The agency methodically goes through the following general principles: 1. who (relevant audiences) 2. why (motivation) 3. what (relevant information) 4. where (placement of information) 5. when (timing) 6. how (methods used to support transparency) The biggest of those is what, i.e. what information needs to be shared. It's a general framework, but a good checklist.

72

1 Kommentar

3 noteworthy acquisitions were announced in #DigitalHealth last week, moving the total to 76 acquisitions in 2024 till date. - On Tuesday, Switzerland-based Mediktor announced the acquisition of Sensely, a San Francisco-based digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. - On Thursday, Carevīve was acquired by Health Catalyst. The acquisition strengthens Health Catalyst's position in the digital healthcare market, expanding its capabilities in patient engagement and care coordination. - On Friday, Doktor.se announced that it acquired competitor Doktor24. The combined entity will provide a comprehensive suite of digital healthcare services, including telemedicine consultations, patient engagement platforms, and data analytics capabilities. Compared to last year, the total number of acquisitions is still trending significantly lower. Till date, the M&A activity in Digital Health has been 14% lower as compared to the same period last year. #Merger #Acquisitions #healthcarefinancing Source: All data from Alpha Edge, the business intelligence tool in HealthTech Alpha

18

1 Kommentar

TOM is a swiss #digitalhealth startup with expertise on #therapies from the #patient perspective. We have developed a new approach that links anonymous patient feedback directly with therapy data/RWD from 350,000 patients to provide much faster and more precise answers then ever before. If you are interested in how we do this, we would be happy to present some of the use cases that we are currently implementing with pharmaceutical companies. Just drop a message to our Co-Founders Redona Hafizi, PhD or Sven Beichler. Fast, safe and anonymous. How patient surveys work in TOM: https://lnkd.in/gzaiP2zd #patientfirst #patientcentricity #realworlddata #patientsvoice

10

“Healthcare makes up almost 20% of GDP” - I often see healthtech startup pitches lead with this. Sure, that might be true. But what’s the point of telling us this?   Are you using this figure to calculate your market size? Because that’s wrong. It doesn’t matter what you’re selling, I can tell you now that it’s wrong. Healthcare is not one market. It comprises many, many smaller markets. Taking a top-down approach inevitably misses the mark.   Are you saying that you will meaningfully reduce this number? Because that’s unrealistic. You alone aren’t going to make a dent in it. Powerful entrenched interests will stop you from taking their market share. Plus, even if you provide a cheaper alternative, you’re just shifting the spend from one place to another and capturing the value - and maximizing your slice of the pie.   Are you assuming that it matters to customers or investors? Because it probably doesn’t. 20% of GDP doesn’t mean anything to anybody, except the federal government and maybe a few economists. It includes physician practices, hospital facilities, post-acute care, prescription drugs, medical equipment, wellness products - everything but nothing in particular. It’s an economic metric, not a financial one. It describes what has taken place in the aggregate. It’s not an input to manipulate.   Should the figure be lower? Probably. The U.S. is an outlier compared to other developed nations. That said, just because the percent of GDP decreases wouldn’t mean we’re moving in the right direction. Yes, it could mean that healthcare is becoming more affordable. But it could also mean that patients are not receiving the care they need. Or that spending in other sectors has gone up.   So it’s a fairly useless data point. One that everybody has heard. One that anybody can regurgitate.   Instead, spend your precious pitching time on what only you can say. The problem only you understand. The insights only you possess. The solution only you can deliver. Anything else is a distraction.   #healthtech #startups #healthcareinnovation #vc

12

2 Kommentare

HLTH Europe is coming to a close today, and that is a good time summarize. 1. We are in an age of AI buzz at the max, almost every panel had AI mentioned multiple times. 2. Medical dat is key, but making it available and integrating with it is still not a simple task in every country, and in order to unlock the value, there is still a road ahead - Standardization, API's and also process. 3. Start ups have amazing concepts and tools, but because of point number two I think it will be time for platform integration approaches as it will become an issue managing so many elements in to health system IT infrastructure. EHR vendors have already started, but it needs to get easier, better and more user friendly. 4. Healthcare is a glocal system - while the research and human body is mostly the same across the global, the nuance and local systems are very different, and maybe in devices, medicines you can usually stick to a product, when it comes to digital and AI solutions the amount of customization, and business models might kill you on the road to commercial viability. Share you thoughts about AI, data and local variabilities

12

2 Kommentare

An open letter to deeptech investors and operators: If you think AI is the biggest thing in healthcare, you’re thinking too narrow. It’s something a lot bigger, of which AI is a part. And it can be described in one word. Yes - one word. One word that I think will describe the future of healthcare. And it’s not just me, the good folks at Celesta Capital and other leading venture firms are all in on this. So what’s the word? I’ll give it to you. It’s Bioconvergence. And AI in healthcare is one aspect of Bioconvergence, specifically, mimicking the human brain for building reasoning capabilities in models. At 5C, our understanding of Bioconvergence is revolutionizing how we detect, diagnose, and monitor diseases. Traditionally, diagnostic techniques have relied on single modalities, such as medical imaging, blood tests, or biopsies. However, these approaches have limitations in terms of sensitivity, specificity, and invasiveness. Bioconvergence offers the opportunity to combine multiple modalities and technologies to create more comprehensive and precise diagnostic tools. So, we are an AI company today, but why am I talking about Bioconvergence? Because one example of bioconvergence in diagnostics is the integration of medical imaging with artificial intelligence (AI) and machine learning. By training AI algorithms on vast datasets of medical images, we can develop systems that can automatically detect and classify abnormalities with high accuracy. This not only improves the speed and consistency of diagnoses but also enables the identification of subtle patterns that may be missed by humans. Another area of bioconvergence in diagnostics is the combination of genomics, proteomics, and metabolomics with computational biology. By analyzing the complex interactions between genes, proteins, and metabolites, we can identify biomarkers that are indicative of specific diseases or disease subtypes. This enables the development of precision diagnostics that can stratify patients based on their molecular profiles, leading to more targeted and effective treatments. And this is just the start of the possibilities of Bioconvergence. Oh, and did I mention? Healthcare is *one* usecase of Bioconvergence. This phenomenon is going to eat up everything, from material science to rocket science.

116

5 Kommentare

Precision medicine company Tempus AI has just filed to go public. Founded in 2015, Tempus has built the world's largest library of clinical and #molecular data, along with an operating system to make this data accessible and useful for patient care. We wrote down a few thoughts. 1️⃣ 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: 𝐬𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲, 𝐭𝐡𝐞𝐧 𝐞𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐨 𝐨𝐭𝐡𝐞𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐚𝐫𝐞𝐚𝐬 Oncology is where the unmet need is the strongest. Having genetic data is crucial for tailoring treatments to patients. One can expect #precision medicine to expand to other therapeutic areas, particularly cardiovascular/cardiometabolic, respiratory diseases, and neurology. As an illustration, Tempus is now expanding into neurology & psychiatry. 2️⃣ 𝐌𝐨𝐬𝐭 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐰𝐞𝐫𝐞 𝐜𝐫𝐞𝐚𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝟐𝟎𝟏𝟎: 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐦𝐚𝐭𝐮𝐫𝐢𝐧𝐠 Many of the precision oncology companies have gone public. Since their IPO, some have been suffering (like Guardant Health), some have been somewhat stable (like SOPHiA GENETICS) and some have skyrocketed (like Exact Sciences). The ability to acquire the broadest and deepest datasets is the key differentiator between winners and losers. And Tempus is leading. 3️⃣ 𝐓𝐞𝐦𝐩𝐮𝐬 𝐡𝐚𝐬 𝐚 𝐬𝐮𝐩𝐞𝐫𝐢𝐨𝐫 𝐝𝐚𝐭𝐚 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 Some players bet on early cancer detection (like GRAIL), some others on EHR/EMR (like Flatiron Health), some on D2C (like 23andMe).... But Tempus, by building the best (digital) infrastructure for large scale genetic sequencing (making it cheap and easy to access), managed to acquire the world's largest library of clinical and molecular data. Additionally, Tempus' CEO Eric Lefkofsky, the former CEO of Groupon, leveraged his connections with C-level executives at major healthcare institutions, positioning Tempus as an enabler for these institutions to be at the forefront of research. 4️⃣ 𝐖𝐞 𝐚𝐥𝐬𝐨 𝐡𝐚𝐯𝐞 𝐬𝐭𝐫𝐨𝐧𝐠 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞, 𝐛𝐮𝐭 𝐧𝐨𝐭 𝐨𝐧 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐬𝐜𝐚𝐥𝐞 𝐚𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒. Roche is leading the charge with major acquisitions like Foundation Medicine and Flatiron Health. However, it has struggled to make a significant breakthrough. It appears that the #healthcare sector is reluctant to allow a leading pharma to gain too much influence in this highly strategic area. Sophia Genetics, based in Switzerland, has been performing well since its IPO in July 2023. However, its market cap of over $300 million is still at least 10 times lower than most precision oncology players in the U.S. Germany precision oncology player Molecular Health has also gained traction recently, striking deals with pharma companies. Europe needs precision #oncology champions, as they are the cornerstone of personalized medicine. ------- Let's discuss this at HLTH Europe in less than 3 weeks in Amsterdam! #healthtech

149

10 Kommentare

Healthcare investment isn't dead quite yet. Encouraging signs from Carta's breakdown of fundraising. Some key notes: #Biotech leads in terms of cash raised #healthtech leads in # of deals More bridge rounds in Q1 suggests some founders were either not ready or unable to raise a primary round despite the sector's overall resilience in fundraising. Encouraging? Or is the mass consolidation / shake-out still to come? Drop your views in the comments - would love to hear other's thoughts. https://lnkd.in/gEe9fGve

2

Here’s your recap of last week’s health IT news 🗞️ 👇 🥼AI Clinician Assistant • Suki : The AI scribe announced an SDK and APIs enabling developers to integrate ambient documentation into their applications. • Apricot: The gen AI pre-seed startup focused on reducing documentation overhead for home health nurses launched. • Tampa General Hospital + Palantir Technologies: The health system and the software platform are partnering to develop an AI care coordination and decision support platform. ☎️ AI Contact Center • Mediktor + Sensely: The AI symptom triage solution acquired the conversational member engagement platform. 📋  Patient Administration • Oracle (Cerner) + Loyal: The EHR now offers integration with the patient engagement solution through its Healthcare Marketplace. • HubSpot: The CRM and marketing platform announced it will now offer HIPAA support and sensitive data tools. 🏥 Provider and Practice Administration • LeanTaaS: The AI-enabled facility management solution released updates including: mobile-first live view of OR schedule, predictive staffing automation, and a gen AI solution allowing decision-makers to glean staffing and scheduling insights. ⚕️ Clinical Operations • Keragon: The HIPAA-compliant automation platform launched out of stealth with a $3M funding round. 🧑‍💻 Virtual and At-Home Care • AvaSure + CLEW: The virtual care platform is partnering with the AI-powered remote patient monitoring and analytics company to improve patient outcomes. 🍎 VBC • Evolent + Machinify, Inc.: The VBC org acquired AI Authorization assets from the AI operating system platform.    • ProgenyHealth, LLC + Wildflower Health: The maternity and NICU case management solution is partnering with the women’s health VBC enabler to “help health plans fill gaps, collapse silos and integrate into existing clinical and operational workflows.”    • Health Catalyst + Carevīve: The population health data and analytics company has completed acquisition of the cancer care management solution. 🧠 Food for Thought: • This article provided an interesting look at Nebraska Medicine’s efforts to design a next-generation hospital room, including the four technologies they’ve selected to anchor their work. https://lnkd.in/em-u-a5v    • McKinsey released a survey of 200 global health system executives on their investment priorities. Among the notable findings, 88% listed AI as an area of high potential impact, yet only 40% have implemented any solution thus far and over 20% don’t have plans to invest in the next two years. https://lnkd.in/eK3CeqQ2

38

4 Kommentare

We often come across individuals who tell us what we do isn’t really needed because an LLM can do it very easily 👀 . Even though we have first-hand experience from our journey on the glaring limitations we often get dismissed. So, needless to say, I am really happy to see this article published in the NEJM that highlighted the following: - No model (GPT-3.5, GPT-4, Gemini Pro, and Llama2-70b) had an exact match rate for generated ICD-9-CM, ICD-10-CM, and CPT codes above 50%, rendering these models unusable as is. This is why solutions such as the ones we are building at Jonda Health leveraging different technologies, including LLMs and our own proprietary algorithms, are required today. To learn more about what we do, please feel free to reach out to myself, Kuben Vather (MBA) or Daniel Wang. #healthdata #medicalcoding #dataplumbing #healthdatainteroperability #semanticinteroperability https://lnkd.in/gE5HZJnp

33

6 Kommentare